N4 Pharma(DE:0GO)
€0.030.00 (0.00%)
DE:0GO
N4 Pharma financials statements
€0.03
At close:0.00 (0.00%)
N4 Pharma (0GO) Ratios
0 Followers
N4 Pharma Ratios
DE:0GO's free cash flow for Q2 2026 was £-744.59K. For the 2026 fiscal year, DE:0GO's free cash flow was increased by £0.00 and operating cash flow was £-744.59K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 11.93 | 6.24 | 14.86 | 27.81 | 11.01 |
| Quick Ratio | 11.93 | 6.24 | 14.86 | 27.81 | 11.01 |
| Cash Ratio | 11.02 | 5.03 | 12.57 | 24.64 | 8.39 |
| Solvency Ratio | -12.30 | -8.52 | -14.44 | -10.28 | -6.15 |
| Operating Cash Flow Ratio | -11.85 | -7.81 | -14.79 | -10.63 | -8.33 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | £ 1.07M | £ 651.40K | £ 1.13M | £ 2.09M | £ 2.13M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.09 | 1.20 | 1.13 | 1.04 | 1.10 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | 0.98 | 0.51 | 0.77 | 1.61 | 0.97 |
| Profitability Margins | |||||
| Gross Profit Margin | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| EBIT Margin | -15199.56% | -16767.37% | -72964.67% | 0.00% | 0.00% |
| EBITDA Margin | -15199.56% | -16767.37% | -68356.37% | 0.00% | 0.00% |
| Operating Profit Margin | -15199.56% | -16767.37% | -72964.67% | 0.00% | 0.00% |
| Pretax Profit Margin | -15199.56% | -16767.37% | -72964.67% | 0.00% | 0.00% |
| Net Profit Margin | -16589.87% | -14542.71% | -64976.96% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | -16632.90% | -15380.39% | -65386.58% | 0.00% | 0.00% |
| Net Income Per EBT | 109.15% | 86.73% | 89.05% | 86.25% | 83.78% |
| EBT Per EBIT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Return on Assets (ROA) | -103.13% | -136.51% | -99.50% | -47.51% | -65.92% |
| Return on Equity (ROE) | -112.64% | -163.52% | -112.54% | -49.28% | -72.50% |
| Return on Capital Employed (ROCE) | -103.14% | -187.44% | -119.38% | -57.13% | -86.54% |
| Return on Invested Capital (ROIC) | -103.14% | -171.94% | -106.98% | -49.28% | -72.55% |
| Return on Tangible Assets | -103.13% | -136.51% | -104.52% | -47.51% | -65.92% |
| Earnings Yield | -31.69% | -59.26% | -61.47% | -29.84% | -19.16% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.10 | 0.05 | 0.01 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 3705.57 | 6749.99 | 32973.72 | 0.00 | 0.00 |
| Days of Sales Outstanding | 3705.57 | 6749.99 | 32973.72 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 3705.57 | 6749.99 | 32973.72 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.01 |
| Free Cash Flow Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.01 |
| Dividend Paid and CapEx Coverage Ratio | -232233.00 | 0.00 | 0.00 | -276087.67 | 0.00 |
| Capital Expenditure Coverage Ratio | -232233.00 | 0.00 | 0.00 | -276087.67 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | -159.85 | -133.41 | -619.10 | 0.00 | 0.00 |
| Free Cash Flow Yield | -30.53% | -54.36% | -58.56% | -24.02% | -21.99% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -3.09 | -1.69 | -1.63 | -3.35 | -5.22 |
| Price-to-Sales (P/S) Ratio | 523.56 | 245.40 | 1057.12 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 3.55 | 2.76 | 1.83 | 1.65 | 3.78 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -3.28 | -1.84 | -1.71 | -4.16 | -4.55 |
| Price-to-Operating Cash Flow Ratio | -3.28 | -1.84 | -1.71 | -4.16 | -4.55 |
| Price-to-Earnings Growth (PEG) Ratio | 0.07 | 0.04 | 0.30 | 0.09 | 0.46 |
| Enterprise Value Multiple | -2.47 | -0.95 | -0.78 | -1.28 | -3.40 |
| Enterprise Value | 2.72M | 1.16M | 1.04M | 1.53M | 6.27M |
| EV to EBITDA | -2.47 | -0.95 | -0.78 | -1.28 | -3.40 |
| EV to Sales | 374.97 | 159.44 | 531.21 | 0.00 | 0.00 |
| EV to Free Cash Flow | -2.35 | -1.20 | -0.86 | -1.85 | -3.54 |
| EV to Operating Cash Flow | -2.35 | -1.20 | -0.86 | -1.85 | -3.54 |
| Tangible Book Value Per Share | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Shareholders’ Equity Per Share | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.09 | 0.08 | 0.10 | 0.14 | 0.16 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.00 | -0.00 | -0.01 | -0.01 | -0.01 |
| Tax Burden | 1.09 | 0.87 | 0.89 | 0.86 | 0.84 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 12.65 | 53.61 | 317.15 | 0.00 | 0.00 |
| SG&A to Revenue | 140.35 | 115.08 | 367.63 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 1.01 | 1.76 | 0.00 | 0.00 |
| Income Quality | 0.96 | 0.87 | 0.95 | 0.80 | 1.15 |
Currency in GBP
